Ferring Pharmaceuticals announces optimisation of operations to accelerate growth
Saint-Prex, Switzerland – 7 October 2025 – Ferring is optimising and aligning its operations with its newly announced Enterprise Model that strengthens its core business and gives it the flexibility to pursue new opportunities.
As part of this optimisation, subject to local employment processes and regulations, Ferring has informed employees in relevant locations of proposals leading to an expected reduction of up to 500 roles globally.
Ferring is undertaking a company-wide initiative designed to sharpen strategic focus, improve cost efficiencies, flexibility, and free up resources for reinvestment in innovation, whilst promoting its financial stability and sustainable growth. These proposed changes include potential geographic relocations of some roles to better reflect strategic priorities. Subject to local consultation, where required, some roles could change, while other capabilities may no longer be required.
Ferring’s intention is to enable continued investment in patient solutions, modern technologies, and business development focused on mid- to late-stage opportunities. We recognise, however, that these changes have a significant personal impact on some of our colleagues, and we are committed to supporting everyone affected with respect, care, and transparency throughout the process.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.
Media contacts:
- Denmark, Singapore & UK: Björn Lindström: bjoern.lindstroem@ferring.com
- Switzerland & France: Sharon Valdettaro: sharon.valdettaro@ferring.com
- United States: Patrick Gorman: patrick.gorman@ferring.com